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Abstract There has been considerable debate about
the utility of pelvic lymph node dissection (PLND)
when performing a radical prostatectomy. Reported
practices vary from those who always perform an
extended PLND to those who employ a predictive
nomogram in their decision making to those who are
increasingly not performing a PLND in low-risk dis-
ease. A Medline search was used to identify relevant
manuscripts dealing with the role of lymphadenectomy
in clinically organ-conWned prostate cancer. A greater
number of lymph nodes (LN) removed and examined
at prostatectomy for prostate cancer appears to
increase the likelihood of Wnding LN metastases and
increase prostate cancer-speciWc survival even in
patients who have histologically uninvolved LN. This
survival beneWt may result from more accurate staging
and possible removal of occult metastases. The need
for and extent of PLND in prostate cancer, especially
in low-risk disease, however, is unlikely.
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Introduction
The incidence of nodal metastases diagnosed during
radical prostatectomy (RP) has declined in recent
years, related to the downward pathologic stage migra-
tion induced by prostate-speciWc antigen (PSA)-based
screening [1, 2]. Lymph node (LN) metastases in clini-
cally localized prostate cancer portends a poor progno-
sis [3]. Therefore, algorithms that include preoperative
risk factors (serum PSA level, clinical stage, and tumor
grade) have since been introduced to identify patients
at low risk of nodal metastasis and in whom pelvic
lymph node dissection (PLND) may not be beneWcial
[4–6]. For prostate cancer patients with a Gleason sum
of 6 or less and a PSA level of 10 ng/ml or less, the like-
lihood of metastatic disease according to the Partin
nomogram is 0–3% [7]. For this reason, and consistent
with most other nomogram predictions, some surgeons
reserve PLND for men with a PSA level greater than
10 ng/ml and Gleason sum greater than 6 [8]. However,
these data are based on experience with a limited
PLND dissection with few LNs being histopathologi-
cally analyzed resulting in an underestimate of the true
pathological stage and incidence of positive nodes.
Therefore, the utility of such nomograms have been
limited by diVerences in sensitivity to discriminate
between low-risk and high-risk patients [9].
Clinical staging
Accurate staging is important, not only for identiWca-
tion of the extent and location of the malignancy but
also, perhaps more importantly, for determination of
malignant potential. In prostate cancer, despite
advances in radiological examinations, computed
tomography (CT) and magnetic resonance imaging
(MRI) have not proven to be suYcient for detection of
LN metastasis in the pelvis [10, 11].
In recent years the sentinel lymph node (SLN) con-
cept has been applied to various malignant tumors.
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where lymphatic Xow from the tumor Wrst arrives [12].
According to the pioneering works of Wawroschek
et al. it was possible to identify SLNs in patients with
prostate cancer with the radioisotope method [13]. By
using a modiWed PLND in 117 patients, the incidence
of LN metastasis was consistent with that of SLNs in 26
of 27 patients with LN metastasis, thus demonstrating
the high sensitivity rate of 96% [13].
Recently, it was also observed that the combination
of SLN lymphocintigraphy and extended PLND
removes more positive nodes than SLN lymphocintig-
raphy alone [14].
As stated earlier, the use of MRI and CT scan to
evaluate LN involvement is not routinely recom-
mended, owing to the low sensitivity (0–30%) in
imaging microscopic disease [15]. Anatomic localiza-
tion of prostatic SLN with fusion imaging of SPECT
and CT scans after intraprostatic injection of Techne-
tium-99m-Nanocolloid identiWed 317 SLN with a
median of 10 per patient (range 3–19) [16]. But since
the objective is to not only identify diseased nodes
but also to remove as many as possible, the role of
preoperative SLN detection remains undetermined.
Specialized techniques, such as high-resolution MRI
used in tandem with the intravenous administration
of lymphotropic superpara-magnetic nanoparticles,
might allow for detection of small and otherwise
undetectable LN disease. In a recent study involving
80 patients with clinical T1, T2, or T3 disease, MRI
with lymphotropic superpara-magnetic nanoparticles
outperformed conventional MRI and nomograms in
the detection of LN-positive disease [17]. An issue of
concern, is that nanoparticles do not adequately
identify nodes with micrometatases yet it is these
patients who are most likely to beneWt from PLND.
Therefore such novel imaging techniques require
further clinical evaluation and validation before
widespread use.
Monoclonal antibody radioimmunoscintigraphy
(i.e., ProstaScint Scan; Cytogen Corporation, Prince-
ton, NJ, USA) has had limited accuracy in the detec-
tion of LN metastases because the antibody targets an
intracellular epitope that is only exposed in dying or
dead cells [18]. Although initially promising, molecular
techniques using reverse transcription polymerase
chain reaction have had varying sensitivities in detect-
ing circulating cancer cells. In addition, a signiWcant
proportion of men with organ-conWned disease in one
study were found to have a positive PSA PCR assay
[19]. Thus, the signiWcance of a positive assay remains
unknown, and positive assays might lead to men being
over staged and denied curative treatment.
In continued eVorts to improve patient outcomes
and to tailor treatment options to individual patient
circumstances, predictive nomograms that estimate the
likelihood of positive nodes for an individual by assign-
ing points for speciWc risk factors have been developed
for predicting pathologic stage and biochemical failure
after deWnitive therapy. However as stated before,
these nomograms are based on limited PLND and
therefore may be imprecise. Recently, Briganti et al.
developed and validated the Wrst nomogram predicting
the probability of LN invasion that accounts for the
number of nodes removed and examined in patients
undergoing PLND of various extents [20]. Based on
their model, the risk of LN invasion for men undergo-
ing RRP increases linearly in proportion to the number
of LN removed. This nomogram was internally vali-
dated and was 76% accurate. While identifying new
factors that add incremental predictive accuracy obvi-
ously helps, the above nomogram depends on its devel-
opment cohort. Primary lymphatic drainage sites of the
prostate may go up to the inferior mesenteric artery
but Briganti and colleagues did not account for this in
their nomogram. In addition, nomogram predictions
must be interpreted as such; they do not make treat-
ment recommendations or provide deWnitive informa-
tion on disease progression or complications associated
with treatment.
PLND template
The actual deWnition of limited/extended PLND for
prostate cancer is variable. The minimal PLND consid-
ers only the obturator fossa; the standard variant also
includes LN along the external iliac vein, whereas the
extended variant is a complete LN dissection along the
obturator fossa and the external, internal, and, in some
cases, common iliac vessels. As determined by cadav-
eric and human studies, the average number of nodes
obtained by extended PLND is 22 [21].
Pelvic lymphadenectomy as a staging procedure
Uniform surgical standards of pelvic staging lympha-
denectomy for prostate cancer cannot be determined
from the current literature. The rationale for locore-
gional staging lymphadenectomy in prostate cancer
lies in the accurate diagnosis of occult micrometasta-
ses in order to stratify patients who might beneWt
from adjuvant therapeutic measures. One study has
shown that early androgen-ablative therapy following
RP in men with node-positive disease is associated with123
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staging could be helpful to select patients for the best
adjuvant treatment. Furthermore, the dissection of LN
(micro)metastases could improve survival.
A limited PLND is not a reliable staging procedure
because it misses >50% of the positive nodes compared
to an extended dissection. Extended PLND has been
shown to increase the yield of both total LN and LN
metastases signiWcantly. Heidenreich et al. reported on
103 patients who had an extended PLND comprising
the external iliac, internal iliac, obturator, and common
iliac LN bilaterally and the presacral nodes [23]. They
compared this group of patients with 100 men who
received only standard PLND. LN metastases were
diagnosed in 26.2% in the extended group and in only
12% in the standard PLND group. Despite negative
obturator LN, positive LN were identiWed in the inter-
nal iliac and presacral regions. Forty-two percent of all
LN metastases were detected outside the regions of
standard PLND. Bader et al. performed a meticulous
PLND along the external iliac vein, the obturator
nerve, and the internal iliac (hypogastric) vessels in
men with clinically organ-conWned disease. Eighty-
eight of 365 men (24%) had positive LN. Internal iliac
LN were positive in 58% and internal iliac LN alone
were positive in 19% of the men [24]. Similar results
have been reported using the laparoscopic approach.
Stone et al. reported twice as many LN removed via
extended than limited laparoscopic PLND (mean 17.8
versus 9.3), and three times as many patients with LN
metastasis in the extended group [7.3% versus 23.1%
(P = 0.02)] [25]. However, the link between the extent
and the yield of PLND was not always conWrmed. The
only randomized study on extended versus limited
PLND was reported by Clark et al. found no diVerence
in the yield of positive nodes with more extended dis-
section (extended 3.2% versus limited 2.4%) [26]. The
two types of dissection were conducted in the same
patient on contralateral sides, however, the majority of
patients had a low probability of LN metastases and
thereby did not require a PLND. Comparing two tech-
niques in a cohort who are unlikely to have positive LN
obviously limits the power of the trial. Even without
this limitation, the number of patients examined was
inadequate for an equivalence study. In addition, 90%
of their patients had T1c or T2a disease, which is
mostly a unilateral disease, and therefore randomly
assigning them to extended PLND on only one side
carries a substantial risk that the extended PLND was
performed on the nontumor bearing side. Also, neither
the number of nodes removed, nor the pathological
specimen assessment were deWned, which would have
introduced an important bias. Therefore, the study
design renders it hard to compare their data with those
of other previous studies.
Taken together, the above data suggest that, in gen-
eral, extended PLND yields higher rates of LN. A pos-
sible reason for the diVerence in the proportion of
positive nodes found at limited and extended PLND is
that approximately one Wfth of the patients with posi-
tive nodes found at extended PLND have the internal
vessels as their sole site of disease [19, 20]. A preferred
anatomical location for positive nodes has not been
identiWed. Since prostate cancer nodal metastases do
not follow a pre-deWned pathway of metastatic spread,
an extended PLND identiWes LN invasion that would
not otherwise be detected by a limited PLND. Impor-
tantly, the above studies demonstrate that up to two
thirds of all patients with LN metastasis have positive
nodes along the internal iliac vessels, an area not
included in a limited PLND.
A therapeutic beneWt of extended lymphadenectomy
Extended lymphadenectomy enhances the accuracy of
surgical staging but if this translates into a survival ben-
eWt has yet to be established. Indeed, the limited value
of a PLND as a staging procedure only without any
therapeutic beneWt is currently increasingly challenged
[27]. The possibility of therapeutic beneWt for PLND in
prostate cancer has been suggested by some studies.
Some studies show that patients with minimal LN
metastases will have better prognosis by removing the
diseased nodes. In 1987, Golimbu et al. retrospectively
analyzed 42 patients with occult nodal disease who
underwent PLND and RRP [28]. In this series, patients
with low tumor bulk and one positive LN had survival
rates comparable to those of matched controls after a
mean follow-up of 5 years. In 1988, Catalona showed
that treatment can be curative even in LN-positive dis-
ease. In a relatively small series of 12 patients with LN
involvement and no adjuvant therapy, 75% remained
recurrence free at 5 years and 58% at 7 years [29]. The
results from Pound et al. for patients with LN microm-
etastasis, revealed a 10-year metastasis-free survival
rate of 68%, again without adjuvant therapy [30]. In
2003, Bader et al. reported on 92 men followed with
histologically proven LN metastases who received no
adjuvant therapy. After 45 months (median), 15 of 39
patients (38.5%) with only one positive node remained
without signs of progression, whereas only 10 and 14%
of patients with two or more positive LN remained dis-
ease free [31].
Prognosis of patients has also been shown to be
depend on the number of positive nodes involved.123
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or two positive LNs had a clinical recurrence-free sur-
vival rate of 70 and 73% at 10 years [32]. By contrast,
men with Wve or more involved nodes had a recur-
rence-free survival rate of only 49%. When stratiWed
by LN density, patients with a density of ¸20% were at
higher risk of clinical recurrence than those with a den-
sity of <20%. A diVerence in PSA progression-free sur-
vival in men with <15% of nodes involved was
reported by Allaf et al. [33]. In these patients, the 5-
year PSA progression-free survival was 43% for the
extended and only 10% for the limited PLND.
Recently, Bader et al. demonstrated that the num-
ber of LN metastases detected is strictly correlated to
the number of nodes removed and that the rate of pN0
patients with tumor progression is higher in patients
with only few nodes removed [34]. Similarly, Joslyn
et al., using the SEER database, concluded that
patients with LN involvement had a signiWcantly
greater number of nodes removed compared with
those with no LN involvement and that extended
PLND reduces the long-term risk of prostate cancer-
related death, even in patients with negative nodes
compared to patients without PLND [35]. One of the
limitations posed by using SEER data is the lack of
information regarding adjuvant hormonal therapy. A
potential explanation for these observations is that a
thorough nodal resection eliminated micrometastases
that were not detected by routine histologic examina-
tion. Recently, Masterson et al. examined the associa-
tion between the number of LNs removed, the number
of positive LNs and disease progression in patients
undergoing PLND and RRP for clinically localized
prostate cancer [36]. Of the 4,611 eligible patients a
median of 9 LNs were removed and positive nodes
were found in 175 patients (3.8%). Overall the number
of LNs removed did not predict freedom from bio-
chemical recurrence (BCR), however, in men without
nodal involvement an increased number of nodes
removed correlated signiWcantly with freedom from
BCR. Recently, an assay that reveals and quantiWes
clinically relevant occult micrometastases in pathologi-
cally negative LN at the time of primary prostate can-
cer therapy was developed [37]. The prognostic
importance of pathologically detected LN metastases
been will established by markedly inferior Wnal out-
come but the new question is whether occult micromet-
astatic in pathologically N0-LN might also be
associated with a reduced prognosis [3].
The above investigators concluded that a signiWcant
beneWt in BCR-free survival might exist for certain
subgroups undergoing the extended dissection. Never-
theless, it is unlikely that men with high-risk disease
will be cured by removing all positive nodes. But, it is
possible that progression-free survival can be pro-
longed when radical surgery and adjuvant therapy are
combined [38]. One possible explanation for the Wnd-
ing of a beneWt to extended dissection is that it might
be an artifact of stage migration (the Will Rogers phe-
nomenon) [39]. A limitation of many such studies is
that the proportion of patients with prostate cancer
with positive nodes is low, and therefore the value of
extended PLND requires a multi-institutional, ran-
domized clinical trial.
By contrast to the above studies, DiMarco et al.
could not conWrm that the extent of PLND aVected
prostate cancer outcome in LN-negative men [40].
They concluded that the eVect of understaging on out-
come is likely to be negligible. As they compared the
results of extended PLND between 1987 and 1989 with
those of a more limited PLND from 1999 to 2000, T-
stage migration, with higher tumor stages in the earlier
period, could explain these results. Because an
extended PLND in the earlier period led to similar
results for disease progression and survival as remov-
ing fewer nodes in a later period, their results imply
that the extended PLND had a therapeutic role for the
earlier cohort.
Although these data suggest the beneWt of extended
PLND at prostatectomy, some argue that it would be
hard to advocate that approach in all patients, particu-
larly those with low risk of LN involvement. The need
for and extent of PLND in prostate cancer, especially
in low-risk disease, is unlikely. Bhatta Dhar et al.
reported a 6-year biochemical relapse-free rate for the
PLND versus no-PLND group of 86 and 88%, respec-
tively and on multivariate analysis, PLND was not an
independent predictor of outcome (P = 0.33). Recently
Schumacher et al. reported that with an extended
PLND in 231 patients with a median serum PSA of
<10 ng/ml (range 0.4–9.98), most positive nodes were
found in the subgroup of patients with a Gleason score
¸7 in the surgical specimen (25%), whereas in patients
with a Gleason score ·6 only 3% had positive nodes
[41]. They concluded that the incidence of LN metasta-
sis is low in patients with a PSA <10 ng/ml and Gleason
score ·6 and in these patients PLND may be unneces-
sary. However, there is a substantial risk of preopera-
tive understaging and undergrading and this must be
considered when counseling patients. Grossfeld et al.
found 30% undergrading and understaging in patients
with a preoperative biopsy Gleason score ·6 [42].
Opponents of extended PLND argue that perform-
ing an extended PLND results in increased morbidity
and higher costs [43]. Morbidity can be kept low
(approx. 2% lymphoceles) if attention is paid to a few123
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the legs, instead of clipping. Hemoclips have tendency
to be torn away during subsequent surgery. (2) Place-
ment of two drains one on each side of the pelvis where
PLND was performed. Drains should be removed
gradually until the total amount drained is less than
50 ml/24 h. (3) Injection of low molecular heparin into
the upper arm instead of the thigh.
In conclusion, a greater number of LN removed and
examined at prostatectomy for prostate cancer appears
to increase the likelihood of Wnding LN metastases and
increase prostate cancer-speciWc survival even in
patients who have histologically uninvolved LN. This
survival beneWt may result from more accurate staging
and possible removal of occult metastases.
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